These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37581593)

  • 1. Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study.
    Olszewski AJ; Phillips TJ; Hoffmann MS; Armand P; Kim TM; Yoon DH; Mehta A; Greil R; Westin J; Lossos IS; Munoz JL; Sit J; Wei MC; Yang A; Chen V; Purev E; Yee DL; Jaeger U
    Blood Adv; 2023 Oct; 7(20):6055-6065. PubMed ID: 37581593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.
    Budde LE; Sehn LH; Matasar M; Schuster SJ; Assouline S; Giri P; Kuruvilla J; Canales M; Dietrich S; Fay K; Ku M; Nastoupil L; Cheah CY; Wei MC; Yin S; Li CC; Huang H; Kwan A; Penuel E; Bartlett NL
    Lancet Oncol; 2022 Aug; 23(8):1055-1065. PubMed ID: 35803286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
    Johnston PB; LaPlant B; McPhail E; Habermann TM; Inwards DJ; Micallef IN; Colgan JP; Nowakowski GS; Ansell SM; Witzig TE
    Lancet Haematol; 2016 Jul; 3(7):e309-16. PubMed ID: 27374464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA.
    Sehn LH; Martelli M; Trněný M; Liu W; Bolen CR; Knapp A; Sahin D; Sellam G; Vitolo U
    J Hematol Oncol; 2020 Jun; 13(1):71. PubMed ID: 32505213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.
    Vitolo U; Trněný M; Belada D; Burke JM; Carella AM; Chua N; Abrisqueta P; Demeter J; Flinn I; Hong X; Kim WS; Pinto A; Shi YK; Tatsumi Y; Oestergaard MZ; Wenger M; Fingerle-Rowson G; Catalani O; Nielsen T; Martelli M; Sehn LH
    J Clin Oncol; 2017 Nov; 35(31):3529-3537. PubMed ID: 28796588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Bartlett NL; Assouline S; Giri P; Schuster SJ; Cheah CY; Matasar M; Gregory GP; Yoon DH; Shadman M; Fay K; Yoon SS; Panizo C; Flinn I; Johnston A; Bosch F; Sehn LH; Wei MC; Yin S; To I; Li CC; Huang H; Kwan A; Penuel E; Budde LE
    Blood Adv; 2023 Sep; 7(17):4926-4935. PubMed ID: 37067952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron emission tomography-adapted therapy in low-risk diffuse large B-cell lymphoma: results of a randomized, phase III, non-inferiority trial.
    Shi Q; He Y; Yi HM; Mu RJ; Jiang XF; Fu D; Dong L; Qin W; Xu PP; Cheng S; Song Q; Chen SJ; Wang L; Zhao WL
    Cancer Commun (Lond); 2023 Aug; 43(8):896-908. PubMed ID: 37403255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
    Munakata W; Izutsu K; Mishima Y; Nagai H; Ishihara Y; Suzumiya J; Kanakura Y; Nanki T; Miyake T; Kawasaki A; Yoshinaga T; Ishizawa K
    Jpn J Clin Oncol; 2023 Oct; 53(10):912-921. PubMed ID: 37486002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
    Thieblemont C; Tilly H; Gomes da Silva M; Casasnovas RO; Fruchart C; Morschhauser F; Haioun C; Lazarovici J; Grosicka A; Perrot A; Trotman J; Sebban C; Caballero D; Greil R; van Eygen K; Cohen AM; Gonzalez H; Bouabdallah R; Oberic L; Corront B; Choufi B; Lopez-Guillermo A; Catalano J; Van Hoof A; Briere J; Cabeçadas J; Salles G; Gaulard P; Bosly A; Coiffier B
    J Clin Oncol; 2017 Aug; 35(22):2473-2481. PubMed ID: 28426350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial.
    Kimani S; Painschab MS; Kaimila B; Kasonkanji E; Zuze T; Tomoka T; Mulenga M; Nyasosela R; Chikasema M; Mtangwanika A; Chawinga M; Mhango W; Nicholas S; Chimzimu F; Kampani C; Krysiak R; Lilly A; Randall C; Seguin R; Westmoreland KD; Montgomery ND; Fedoriw Y; Gopal S
    Lancet Glob Health; 2021 Jul; 9(7):e1008-e1016. PubMed ID: 34022150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group.
    Peyrade F; Bologna S; Delwail V; Emile JF; Pascal L; Fermé C; Schiano JM; Coiffier B; Corront B; Farhat H; Fruchart C; Ghesquieres H; Macro M; Tilly H; Choufi B; Delarue R; Fitoussi O; Gabarre J; Haioun C; Jardin F
    Lancet Haematol; 2017 Jan; 4(1):e46-e55. PubMed ID: 28041583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study.
    Kim YR; Kim JS; Kim WS; Eom HS; Yang DH; Bae SH; Kim HJ; Lee JH; Oh SJ; Yoon SS; Kwak JY; Choi CW; Kim MK; Oh SY; Kang HJ; Nam SH; Shim H; Park JS; Mun YC; Suh C;
    Cancer Res Treat; 2023 Oct; 55(4):1355-1362. PubMed ID: 36996864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
    Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
    Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of atezolizumab with rituximab and CHOP in previously untreated diffuse large B-cell lymphoma.
    Younes A; Burke JM; Cheson BD; Diefenbach CS; Ferrari S; Hahn UH; Hawkes EA; Khan C; Lossos IS; Musuraca G; Tani M; Vitolo U; Yuen S; Raval A; Shivhare M; Nielsen TG; Sellam G; Sharman JP
    Blood Adv; 2023 Apr; 7(8):1488-1495. PubMed ID: 36287231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL.
    Martin P; Bartlett NL; Chavez JC; Reagan JL; Smith SM; LaCasce AS; Jones J; Drew J; Wu C; Mulvey E; Revuelta MV; Cerchietti L; Leonard JP
    Blood; 2022 Feb; 139(8):1147-1159. PubMed ID: 34428285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial.
    Vitolo U; Chiappella A; Franceschetti S; Carella AM; Baldi I; Inghirami G; Spina M; Pavone V; Ladetto M; Liberati AM; Molinari AL; Zinzani P; Salvi F; Fattori PP; Zaccaria A; Dreyling M; Botto B; Castellino A; Congiu A; Gaudiano M; Zanni M; Ciccone G; Gaidano G; Rossi G;
    Lancet Oncol; 2014 Jun; 15(7):730-7. PubMed ID: 24831981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
    Cunningham D; Hawkes EA; Jack A; Qian W; Smith P; Mouncey P; Pocock C; Ardeshna KM; Radford JA; McMillan A; Davies J; Turner D; Kruger A; Johnson P; Gambell J; Linch D
    Lancet; 2013 May; 381(9880):1817-26. PubMed ID: 23615461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study.
    Budde LE; Assouline S; Sehn LH; Schuster SJ; Yoon SS; Yoon DH; Matasar MJ; Bosch F; Kim WS; Nastoupil LJ; Flinn IW; Shadman M; Diefenbach C; O'Hear C; Huang H; Kwan A; Li CC; Piccione EC; Wei MC; Yin S; Bartlett NL
    J Clin Oncol; 2022 Feb; 40(5):481-491. PubMed ID: 34914545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.